Jasper Therapeutics/$JSPR
1D1W1MYTD1Y5YMAX
Capital at risk
About Jasper Therapeutics
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.
- Ticker
- $JSPR
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- -
- Headquarters
- Redwood City, United States
JSPR Metrics
BasicAdvanced
$21M
-
-
-
-
Price and volume
Market cap
$21M
52-week high
$2.69
52-week low
$0.32
Average daily volume
589K
Financial strength
Profitability
Management effectiveness
Valuation
Growth
What the Analysts think about JSPR
Analyst ratings (Buy, Hold, Sell) for Jasper Therapeutics stock.
Analyst projections of the future price of Jasper Therapeutics stock.
JSPR Financial Performance
Revenues and expenses
JSPR Earnings Performance
Company profitability
Upcoming events
No upcoming events
JSPR News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.